SCHEMBL277538

SCHEMBL277538

Clc1[c]scc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1177771 0.71
SCHEMBL3525558 0.71
SCHEMBL1177773 0.71
SCHEMBL9218163 0.66
SCHEMBL8049697 0.63
SCHEMBL353919 0.63 HSD11B1 (0.30)
SCHEMBL3696888 0.63
SCHEMBL3620424 0.53
SCHEMBL319580 0.53
SCHEMBL15902500 0.48

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2782565-B1 USE OF ARYL AND HETARYL CARBOXAMIDES AS ENDOPARASITICIDES BAYER IP GMBH (DE) 2019-11-06 EP claimed
EP-2920163-B1 PYRIDYLOXYAL ALKYL CARBOXAMIDES AND THEIR USE AS ENDOPARASITICIDES AND NEMATICIDE BAYER CROPSCIENCE AG (DE) 2018-05-02 EP claimed
US-9422276-B2 Use of aryl and hetaryl carboxamides as endoparasiticides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-08-23 US claimed
US-20140323736-A1 USE OF ARYL AND HETARYL CARBOXAMIDES AS ENDOPARASITICIDES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-10-30 US claimed
EP-2782565-A1 USE OF ARYL AND HETARYL CARBOXAMIDES AS ENDOPARASITICIDES Bayer Intellectual Property GmbH (DE) 2014-10-01 EP claimed
WO-2013076230-A1 USE OF ARYL AND HETARYL CARBOXAMIDES AS ENDOPARASITICIDES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-05-30 WO claimed
US-7759390-B2 chemokine receptor 9(CCR9) antagonists such as, 5-Chloro-thiophene-2-sulfonic acid (4-cyano-2-methyl-phenyl)-amide, used for treating autimmune and inflammatory diseases, transplantat rejection and cancer NOVARTIS AG (CH) 2010-07-20 US claimed
US-20100029649-A1 PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-02-04 US claimed
EP-2074107-A2 TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2009-07-01 EP claimed
US-20080300295-A1 Inhibitors of Ccr9 Activity NOVARTIS AG (CH) 2008-12-04 US claimed
EP-1966182-A1 INHIBITORS OF CCR9 ACTIVITY Novartis AG (CH) 2008-09-10 EP claimed
WO-2008057254-A2 TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS WYETH (US) 2008-05-15 WO claimed
EP-1848714-A2 PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2007-10-31 EP claimed
WO-2007071440-A1 INHIBITORS OF CCR9 ACTIVITY NOVARTIS AG (CH) 2007-06-28 WO claimed
WO-2007014008-A2 BENZENESULFONAMIDE INHIBITOR OF CCR2 CHEMOKINE RECEPTOR GLAXO GROUP LIMTED (GB) 2007-02-01 WO claimed
WO-2006084017-A2 PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-08-10 WO claimed
US-20060178388-A1 Phenyl-substituted pyrimidine compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2006-08-10 US claimed
US-6248773-B1 VISION DEFECTS ALLERGAN SALES, INC. 2001-06-19 US claimed
EP-1032395-A1 CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS Allergan Sales, Inc. (US) 2000-09-06 EP claimed
WO-1999025358-A1 CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS ALLERGAN SALES, INC. (US) 1999-05-27 WO claimed